GE HealthCare (GEHC) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and GE HealthCare published the results on October 28, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. GE HealthCare reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted EPS (non-GAAP), which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• In the second quarter of 2026 GE HealthCare combined its Imaging and Advanced Visualization Solutions businesses into one segment, Advanced Imaging Solutions, and recast prior periods. It now reports three segments instead of four.
• Other is HealthCare Financial Services, which is not an operating segment.
• GE HealthCare acquired Intelerad on March 18, 2026 for about $2,293 million; it is part of AIS and adds to reported, not organic, growth.

Source: GE HealthCare Q3 2026 results, October 28, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How GE HealthCare splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• GE HealthCare's Advanced Imaging Solutions (AIS) revenue was $3.9 billion in Q3 2026, up 6% from $3.6 billion in Q3 2025, 70% of total revenue.
• GE HealthCare's Pharmaceutical Diagnostics (PDx) revenue was $846 million in Q3 2026, up 13% from $749 million in Q3 2025, 15% of total revenue.
• GE HealthCare's Patient Care Solutions (PCS) revenue was $793 million in Q3 2026, up 8% from $731 million in Q3 2025, 14% of total revenue.
• GE HealthCare's Other revenue was $2.0 million in Q3 2026, down 87% from $15.0 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

GE HealthCare gives its outlook as a table in the release. Updated 2026 figures: organic revenue growth of about 4.0% (previously 3.0% to 4.0%), adjusted EBIT margin of 15.5% to 15.7% (previously 15.4% to 15.7%), adjusted effective tax rate of 20.0% to 21.0% (reaffirmed), adjusted EPS of $4.95 to $5.05 (previously $4.80 to $5.00) and free cash flow of $1.6 billion or more (previously about $1.6 billion).

In its Q3 2026 release, GE HealthCare said:

“For the full-year 2026, the Company raises guidance as follows:”

“The Company provides its outlook on a non-GAAP basis.”

Source: GE HealthCare Q3 2026 release, Oct 28, 2026.

This is the company's own guidance as of Oct 28, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the GEHC forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted EPS, each as first reported in that quarter's release. GE HealthCare published preliminary Q2 2026 figures on July 23, 2026, alongside a CFO transition announcement; the full Q2 release followed on July 29.

We do not hold a confirmed date for GE HealthCare's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 28, 2026

Advanced Imaging Solutions is most of GE HealthCare's revenue: $3,873 million of $5,513 million in Q3 2026. Within it, Radiology brought in $2,463 million, Procedural Guidance $772 million and Specialized Ultrasound $639 million. Pharmaceutical Diagnostics had revenue of $846 million and Patient Care Solutions $793 million. (GE HealthCare Q3 2026 release, Oct 28, 2026; GE HealthCare Form 10-Q, Q3 2026, Oct 28, 2026)

Revenue grew 7.2% as reported and 6.2% organically. AIS grew 6.1%, helped by the Intelerad acquisition ($68 million of acquired revenue in the quarter), with organic growth of 4.5% that GE HealthCare credits to CT, CardioVascular & Interventional Solutions and Surgical Innovations. PDx grew 13.0% on contrast media and radiopharmaceutical volume and price, and PCS grew 8.5% on improved product fulfillment in Monitoring and Maternal Infant Care. (GE HealthCare Q3 2026 release, Oct 28, 2026; GE HealthCare Form 10-Q, Q3 2026, Oct 28, 2026)

Sales of products were $3,602 million and sales of services $1,911 million. Services grew 8.1%, which GE HealthCare attributes to the Intelerad acquisition and growth in customer contractual agreements. Remaining performance obligations were $16,113 million at September 30, 2026, of which $10,761 million was services. (GE HealthCare Q3 2026 release, Oct 28, 2026; GE HealthCare Form 10-Q, Q3 2026, Oct 28, 2026)

By region, United States and Canada revenue rose 13.3% to $2,672 million, with growth across all segments. EMEA fell 0.4% to $1,354 million on unfavorable currency, the China region rose 7.1% to $586 million, mainly on favorable currency and AIS growth, and Rest of World rose 2.6% to $901 million. (GE HealthCare Form 10-Q, Q3 2026, Oct 28, 2026)

GE HealthCare's GAAP diluted EPS of $1.36 was above its adjusted EPS of $1.34 in Q3 2026. Adjusted EPS adds back restructuring costs, acquisition-related charges, Spin-Off and separation costs and amortization of acquisition-related intangible assets ($0.13 a share), and takes out non-operating benefit income ($0.11), tariff refunds ($0.02) and other tax adjustments ($0.08), the last including a foreign tax audit settlement. (GE HealthCare Q3 2026 release, Oct 28, 2026)

A lower tax rate helped GAAP earnings: the effective tax rate fell to 17.1% from 27.8% a year earlier, while the adjusted rate was 22.0% against 21.8%. Net income attributable to GE HealthCare rose 37.9% to $615 million, and diluted shares fell to 453 million from 457 million. (GE HealthCare Q3 2026 release, Oct 28, 2026)

GE HealthCare repurchased $300 million of stock in the first nine months of 2026 and had $500 million left under its repurchase authorization at September 30, 2026. It did not repurchase shares in the third quarter. (GE HealthCare Q3 2026 release, Oct 28, 2026; GE HealthCare Form 10-Q, Q3 2026, Oct 28, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

GE HealthCare gives full-year guidance in its release, on a non-GAAP basis, and raised it with Q3 2026. It now expects organic revenue growth of about 4.0% (previously 3.0% to 4.0%), adjusted EPS of $4.95 to $5.05 (previously $4.80 to $5.00) and free cash flow of $1.6 billion or more, and reaffirmed an adjusted effective tax rate of 20.0% to 21.0%. (GE HealthCare Q3 2026 release, Oct 28, 2026)

GE HealthCare also announced plans to acquire SOFIE Biosciences for $945 million in cash, expected to close in the first half of 2027, subject to regulatory approvals. (GE HealthCare Q3 2026 release, Oct 28, 2026)

A consensus figure is the average of the models published by the analysts who cover GE HealthCare, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones GE HealthCare's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning GEHC is on is GEHC a buy or a sell?, what analysts expect next is on the GEHC forecast, and what the company does is on the GE HealthCare (GEHC) stock page.

Every number on this page can be traced to a document GE HealthCare published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.